HIV Vaccines: Intersections of Basic and Clinical Science
Apr 16–19, 2026 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Penny L Moore, Marit van Gils, and Kevin O. Saunders
×
-
Apr 16–19, 2026 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers: Penny L Moore, Marit van Gils, and Kevin O. Saunders
Penny L Moore, PhD
University of the Witwatersrand and National Institute for Communicable Diseases
Marit van Gils, PhD
Amsterdam UMC
Kevin O. Saunders, PhD
Duke University
Available Formats:
Supported by the Directors' Fund
Livestream
In Person
On Demand
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandThursday, April 16, 2026
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
3rd Floor Foyer
Welcome Mixer
6:00–8:00 PM
3rd Floor Foyer
Friday, April 17, 2026
Breakfast
7:00–8:00 AM
Summit Gallery
Welcome Remarks (Joint)
8:00–8:10 AM
Breckenridge Ballroom
Keynote Address (Joint)
8:10–9:00 AM
Breckenridge Ballroom
Alexandra Trkola, University of Zürich
HIV Vaccines: Learning from the Swiss X-BNAb Cohort for Prevention and Cure
HIV Vaccines: Learning from the Swiss X-BNAb Cohort for Prevention and Cure
Immune Interventions Interfacing HIV Prevention and Cure (Joint)
9:00–11:30 AM
Breckenridge Ballroom
Mauricio A. Martins, University of Florida
Promoting Persistent bNAb Expression in NHPs through AAV-Mediated Gene Transfer
Promoting Persistent bNAb Expression in NHPs through AAV-Mediated Gene Transfer
Devi SenGupta, Gilead Sciences, Inc.
Long-acting ART in HIV Prevention and Cure
Long-acting ART in HIV Prevention and Cure
Leonidas Stamatatos, Fred Hutchinson Cancer Research Center
Vaccination of PLWH, using 426C Derived Immunogens
Vaccination of PLWH, using 426C Derived Immunogens
Cristina Ceriani, Emory University
Short Talk: Influence of SIV Gag Vaccination on CD8⁺ T Cell Immunity and SIV Viral Dynamics
Short Talk: Influence of SIV Gag Vaccination on CD8⁺ T Cell Immunity and SIV Viral Dynamics
Nicolas M Galvez Arriagada, Ragon Institute of Mass General, MIT and Harvard
Short Talk: Vectored Delivery of bNAbs Prevents Rebound of Clinical HIV Isolate During Antiretroviral Therapy Interruption
Short Talk: Vectored Delivery of bNAbs Prevents Rebound of Clinical HIV Isolate During Antiretroviral Therapy Interruption
Coffee Break
9:30–9:50 AM
1st Floor Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Breckenridge Ballroom
Poster Setup
11:30–1:00 PM
Peaks 1 - 3
On Own for Lunch
11:30–5:00 PM
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Symposia Spotlight 1: Engineering Immunity to Control and Clear HIV
2:30–4:30 PM
Colorado Ballroom
Matthew Clark, Duke University
Cross-Clade HIV-1 Neutralizing Antibodies With Characteristics of bNAbs, Including VRC01, in Children
Cross-Clade HIV-1 Neutralizing Antibodies With Characteristics of bNAbs, Including VRC01, in Children
Xuejun Chen †, NIAID, National Institutes of Health
Three Sequential Escalating-Dose Immunizations Elicit VRC01-Class Antibody-Mediated Tier 2 HIV-1 Serum Neutralization in a Highly Stringent Mouse Model
Three Sequential Escalating-Dose Immunizations Elicit VRC01-Class Antibody-Mediated Tier 2 HIV-1 Serum Neutralization in a Highly Stringent Mouse Model
Ria Goswami †, Weill Cornell Medicine
Germline-Targeting HIV SOSIP Trimer Immunizations Dampened Post-Rebound SHIV Loads in Infant Macaques
Germline-Targeting HIV SOSIP Trimer Immunizations Dampened Post-Rebound SHIV Loads in Infant Macaques
James A Counts †, Duke University
Sequential Vaccination Elicits VH1-46 Class Orthologous Antibodies with Heterologous Reactivity and Neutralization Targeting the CD4-Binding Site In Rhesus Macaques
Sequential Vaccination Elicits VH1-46 Class Orthologous Antibodies with Heterologous Reactivity and Neutralization Targeting the CD4-Binding Site In Rhesus Macaques
Anna Romanov †, Brigham & Women's Hospital, Harvard Medical School
DNA Origami Vaccines Program Antigen-Focused Germinal Centers
DNA Origami Vaccines Program Antigen-Focused Germinal Centers
Christopher A Cottrell †, The Scripps Research Institute
Sequential Boosting with mRNA/LNP Immunogens Drives VRC01-Class Precursors B Cells To Acquire Key Mutations Allowing For Binding To Heterologous Wildtype HIV Env Trimers with the N276 Glycan
Sequential Boosting with mRNA/LNP Immunogens Drives VRC01-Class Precursors B Cells To Acquire Key Mutations Allowing For Binding To Heterologous Wildtype HIV Env Trimers with the N276 Glycan
Tom G Caniels †, Amsterdam UMC
A Germline-Targeting Prime-Boost Regimen Drives Heterologous Neutralization Breadth of VRC01-class B Cells
A Germline-Targeting Prime-Boost Regimen Drives Heterologous Neutralization Breadth of VRC01-class B Cells
Jerome Edwards †, Fred Hutchinson Cancer Center
A Germline-Targeting Env-derived Immunogen Activates both VRC01- and CH235-class Naïve B Cells in a Phase 1 Clinical Trial
A Germline-Targeting Env-derived Immunogen Activates both VRC01- and CH235-class Naïve B Cells in a Phase 1 Clinical Trial
Coffee Available
4:30–5:00 PM
3rd Floor Foyer
Keeping up with the Changing HIV Envelope
5:00–7:00 PM
Colorado Ballroom
Penny L Moore, University of the Witwatersrand and National Institute for Communicable Diseases
African bNAb Immunogens
African bNAb Immunogens
Margaret E. Ackerman, Dartmouth College
Fc Effector Function in HIV Infection and Vaccination
Fc Effector Function in HIV Infection and Vaccination
Aime Marcel Simon Tongo Passo, Center for Research on Emerging and Re-Emerging Diseases (CREMER/IMPM)
Viral Diversity in Central Africa: Known and Unknowns
Viral Diversity in Central Africa: Known and Unknowns
Gnana Gnanakaran, Los Alamos National Laboratory
Conformation of HIV Env Trimer on Intact Virions
Conformation of HIV Env Trimer on Intact Virions
Ashwin N Skelly †, University of Pennsylvania
Consistent Induction of V3-Glycan Broadly Neutralizing Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design
Consistent Induction of V3-Glycan Broadly Neutralizing Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 1
7:30–10:00 PM
Peaks 1 - 3
Saturday, April 18, 2026
Breakfast
7:00–8:00 AM
Summit Gallery
The Vaccine Pipeline: Integrating Basic and Clinical Insights
8:00–11:00 AM
Colorado Ballroom
Sallie R. Permar †, Weill Cornell Medical Center
Talk Title to be Announced
Talk Title to be Announced
Richard T. Wyatt, The Scripps Research Institute
Triggering bNAbs in Non-Human Primates
Triggering bNAbs in Non-Human Primates
Persephone Borrow, University of Oxford
Creating an Immune Environment Favorable for HIV-1 bnAb Induction
Creating an Immune Environment Favorable for HIV-1 bnAb Induction
Louis J. Picker, Oregon Health & Science University
Progress in CMV based Vaccines
Progress in CMV based Vaccines
Hlelolwenkosi Z Mlimi †, University of KwaZulu-Natal - Nelson R. Mandela School of Medicine
Short Talk: Immunological and Genetic Features Associated with The Development of Broadly Neutralizing Antibodies and Fc-Effector Functions in People Living with HIV-1 Subtype C
Short Talk: Immunological and Genetic Features Associated with The Development of Broadly Neutralizing Antibodies and Fc-Effector Functions in People Living with HIV-1 Subtype C
Lily Zemelko, University of California - San Francisco (UCSF)
Short Talk: HIV DNA Therapeutic Vaccination Durably Boosts HIV-Specific CD8+ T Cell Magnitude and Proliferative Responses
Short Talk: HIV DNA Therapeutic Vaccination Durably Boosts HIV-Specific CD8+ T Cell Magnitude and Proliferative Responses
Coffee Break
9:00–9:20 AM
3rd Floor Foyer
Poster Setup
11:00–1:00 PM
Peaks 1 - 3
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Panel: Perspectives: Personalized Medicine & Patient-Centered Strategies (Joint)
1:30–2:45 PM
Breckenridge Ballroom
Career Roundtable (Joint)
3:00–4:30 PM
Breckenridge Ballroom
Coffee Available
4:30–5:00 PM
3rd Floor Foyer
Targeting the Needle in the Haystack: Clinical Trials of Germline Targeting Immunogens
5:00–7:00 PM
Colorado Ballroom
Kevin O. Saunders, Duke University
Induction of HCDR3-Binding and CD4 Mimicking Antibodies in HVTN300 and HVTN309
Induction of HCDR3-Binding and CD4 Mimicking Antibodies in HVTN300 and HVTN309
Eunice Wambui Nduati, KEMRI, Wellcome Trust
Germline Targeting Immunogens and Precursors in African Populations
Germline Targeting Immunogens and Precursors in African Populations
Marit van Gils, Amsterdam UMC
Germline Targeting Immunogens in Human Clinical Trials; C101, C107, C110
Germline Targeting Immunogens in Human Clinical Trials; C101, C107, C110
Rachael Parks †, Fred Hutch
Short Talk: N332-GT5 Germline-Targeting Immunogen Elicits BG18-bnAb Precursors in a Phase I, Human Clinical Trial (HVTN 144)
Short Talk: N332-GT5 Germline-Targeting Immunogen Elicits BG18-bnAb Precursors in a Phase I, Human Clinical Trial (HVTN 144)
Catarina Mendes Silva †, Amsterdam UMC
Short Talk: Proof-of-Concept Induction of HIV Broadly Neutralizing Antibody Lineages by Vaccination In Humans
Short Talk: Proof-of-Concept Induction of HIV Broadly Neutralizing Antibody Lineages by Vaccination In Humans
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Poster Session 2
7:30–10:00 PM
Peaks 1 - 3
Sunday, April 19, 2026
Breakfast
7:00–8:00 AM
Summit Gallery
Looking to the Future: New Tools, Platforms and Delivery Systems
8:00–11:00 AM
Colorado Ballroom
Eric A. Appel, Stanford University
Injectable Hydrogel Depot Technologies for Sustained Delivery of Vaccines
Injectable Hydrogel Depot Technologies for Sustained Delivery of Vaccines
Shannon Miller, Inimmune Corporation
Adjuvants for Mucosal Immunity
Adjuvants for Mucosal Immunity
Rory Henderson, Duke University
Large Language Models to Identify bnAbs and Design Vaccines to Them
Large Language Models to Identify bnAbs and Design Vaccines to Them
Nitesh Mishra †, The Scripps Research Institute
Short Talk: De Novo, Machine Learning Enabled Discovery of Broadly Neutralizing Unmutated Human Antibodies Against HIV-1
Short Talk: De Novo, Machine Learning Enabled Discovery of Broadly Neutralizing Unmutated Human Antibodies Against HIV-1
Hongying Duan †, NIH/VRC
Short Talk: Vaccine Elicitation of HIV-1 Cross-strain Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques
Short Talk: Vaccine Elicitation of HIV-1 Cross-strain Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques
Austin Kriews †, The Wistar Institute
Short Talk: Exposure to the HIV-1 gp41 Base Redirects the Specificity of Broadly Neutralizing Antibody Lineages
Short Talk: Exposure to the HIV-1 gp41 Base Redirects the Specificity of Broadly Neutralizing Antibody Lineages
Kshitij Wagh, Duke University
Short Talk: Induction of V2-apex Broadly-Neutralizing Antibodies by Signature-Based Prime and Boost mRNA Immunogens in Rhesus Macaques
Short Talk: Induction of V2-apex Broadly-Neutralizing Antibodies by Signature-Based Prime and Boost mRNA Immunogens in Rhesus Macaques
Coffee Break
9:00–9:20 AM
3rd Floor Foyer
On Own for Lunch
11:00–5:00 PM
Meet the Editors (Joint)
1:15–2:15 PM
Breckenridge Ballroom
Symposia Spotlight 2: Novel Approaches to Probe HIV Latency and Persistence
2:30–4:30 PM
Colorado Ballroom
Fabian-Alexander Schleich †, Karolinska Institutet
Vaccination Of Nonhuman Primates Elicits a Broadly Neutralizing Antibody Lineage Targeting a Quaternary Epitope on the HIV-1 Env trimer
Vaccination Of Nonhuman Primates Elicits a Broadly Neutralizing Antibody Lineage Targeting a Quaternary Epitope on the HIV-1 Env trimer
Joshua Carter, Stanford University
Minimally Mutated Silent Face Antibodies Enable Germline-targeted Vaccine Design for the Silent Face Epitope
Minimally Mutated Silent Face Antibodies Enable Germline-targeted Vaccine Design for the Silent Face Epitope
Lorie Marchitto, University of Pennsylvania
Enhanced B Cell Priming Leads to Rapid Induction of Broadly Neutralizing HIV-1 Apex Antibodies
Enhanced B Cell Priming Leads to Rapid Induction of Broadly Neutralizing HIV-1 Apex Antibodies
Severin Coleon †, Duke Human Vaccine Institute (DHVI)
Priming Diverse V2 Apex Antibodies with Unique HCDR3 Motifs Using Germline-Targeting HIV-1 Env Ferritin Nanoparticles in Rhesus Macaques
Priming Diverse V2 Apex Antibodies with Unique HCDR3 Motifs Using Germline-Targeting HIV-1 Env Ferritin Nanoparticles in Rhesus Macaques
Rumi Habib †, University of Pennsylvania
Env-Antibody Coevolution Identifies B Cell Priming as the Principal Bottleneck to HIV-1 V2 Apex Broadly Neutralizing Antibody Development
Env-Antibody Coevolution Identifies B Cell Priming as the Principal Bottleneck to HIV-1 V2 Apex Broadly Neutralizing Antibody Development
Tianling Ou †, Broad Institute
Sequential Immunogens Drive Affinity Maturation of HIV-1 V2-Apex Broadly Neutralizing Antibody Precursors
Sequential Immunogens Drive Affinity Maturation of HIV-1 V2-Apex Broadly Neutralizing Antibody Precursors
Kevin Wiehe †, Duke University
Reliable Elicitation of Broadly Neutralizing Antibodies in the Serum of V3 Glycan bnAb UCA Knock-in Mice Immunized with a 4-Immunogen Vaccine Regimen
Reliable Elicitation of Broadly Neutralizing Antibodies in the Serum of V3 Glycan bnAb UCA Knock-in Mice Immunized with a 4-Immunogen Vaccine Regimen
Jon Steichen †, The Scripps Research Institute
Germline-Targeting Vaccination Elicits HIV Broadly Neutralizing Antibodies In Nonhuman Primates
Germline-Targeting Vaccination Elicits HIV Broadly Neutralizing Antibodies In Nonhuman Primates
Coffee Available
4:30–5:00 PM
1st Floor Foyer
B Cell Responses and Broadly-Neutralizing Antibodies: Trials and Tribulations (Joint)
5:00–6:45 PM
Breckenridge Ballroom
Marina F. Caskey, Rockefeller University
Combined Immunotherapy with IL-15 Agonists and Broadly-Neutralizing Antibodies
Combined Immunotherapy with IL-15 Agonists and Broadly-Neutralizing Antibodies
Paula M. Cannon, University of Southern California, Keck School of Medicine
Engineering B Cells as in vivo bnAb Factories
Engineering B Cells as in vivo bnAb Factories
William Schief, Moderna, Scripps, and IAVI
Combining Germline Targeting Approaches Across Diverse bNAb Epitopes
Combining Germline Targeting Approaches Across Diverse bNAb Epitopes
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Breckenridge Ballroom
Social Hour with Dinner
7:00–8:00 PM
Summit Gallery
Cash Bar
8:00–9:00 PM
Peaks 1 - 3
Entertainment
8:00–9:00 PM
Monday, April 20, 2026
Departure
12:00–11:59 PM
Subscribe for Updates